Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia

Leukemia

Volumn 17, Issue 1, 2003, Pages 17-25

  Tissing, W J E ^a   Meijerink, J P P ^a   den Boer, M L ^a   Pieters, R ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; Apoptosis; Childhood; Glucocorticoid; Glucocorticoid receptor; Resistance

Indexed keywords

CHAPERONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MYC PROTEIN; RNA; TRANSCRIPTION FACTOR AP 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CHILDHOOD LEUKEMIA; COMPLEX FORMATION; CYTOTOXICITY; DRUG SENSITIVITY; DRUG USE; GENE REPRESSION; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC VARIABILITY; HUMAN; MEDICAL RESEARCH; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; RNA SPLICING; TRANSACTIVATION;

EID: 0037268987     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402733     Document Type: Review

References (119)

1. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
2. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G. Die corticosteroid-abhangige dezemierung der leukamiezellzahl im blut als prognose-faktor bei der akuten lymphoblastischen leukemie im kindesalter (therapiestudie ALL-BFM 83). Klin Padiatr 1986; 199: 151-160.
3. Arico M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, Zanesco L, Rondelli R, Pession A, Masera G. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer 1995; 75: 1684-1693.
4. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, Gadner H, Riehm H, Schrappe M. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217.
5. Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V, Reiter A, Valsecchi MG, Gadner H, Basso G, Bartram CR, Lampert F, Riehm H, Masera G. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998; 92: 2730-2741.
6. Pieters R, Huismans DR, Loonen AH, Hahlen K, van der Does-van den Berg A, van Wering ER, Veerman AJ. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 399-403.
7. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van Der Does-Van Den Berg A. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997; 90: 2723-2729.
8. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997; 89: 2959-2965.
9. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998; 92: 259-266.
10. Pieters R, den Boer ML, Durian M, Janka C, Schmiegelow K, Kaspers GJ, van Wering ER, Veerman AJ. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - implications for treatment of infants. Leukemia 1998; 12: 1344-1348.
11. Maung ZT, Reid MM, Matheson E, Taylor PR, Proctor SJ, Hall AG. Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Br J Haematol 1995; 91: 93-100.
12. Styczynski J, Pieters R, Huismans DR, Schuurhuis GJ, Wysocki M, Veerman AJ. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 813-818.
13. Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K, Kaspers GJ, van Wering ER, Hartmann R, Henze G. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861-3868.
14. Theriault A, Boyd E, Harrap SB, Hollenberg SM, Connor JM. Regional chromosomal assignment of the human glucocorticoid receptor gene to 5q31. Hum Genet 1989; 83: 289-291.
15. Hollenberg SM, Evans RM. Multiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell 1988; 55: 899-906.
16. Tao Y, Williams-Skipp C, Scheinman RI. Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-{kappa}B and induction of apoptosis. J Biol Chem 2001; 276: 2329-2332.
17. Dahlman-Wright K, Wright A, Gustafsson JA, Carlstedt-Duke J. Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five amino acids. J Biol Chem 1991; 266: 3107-3112.
18. Zilliacus J, Wright AP, Carlstedt-Duke J, Gustafsson JA. Structural determinants of DNA-binding specificity by steroid receptors. Mol Endocrinol 1995; 9: 389-400.
19. Picard D, Yamamoto KR. Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J 1987; 6: 3333-3340.
20. Hollenberg SM, Giguere V, Segui P, Evans RM. Colocalization of DNA-binding and transcriptional activation functions in the human glucocorticoid receptor. Cell 1987; 49: 39-46.
21. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; 94: 557-572.
22. Defranco DB. Role of molecular chaperones in subnuclear trafficking of glucocorticoid receptors. Kidney Int 2000; 57: 1241-1249.
23. Beato M. Gene regulation by steroid hormones. Cell 1989; 56: 335-344.
24. Tsai SY, Carlstedt-Duke J, Weigel NL, Dahlman K, Gustafsson JA, Tsai MJ, O'Malley BW. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell 1988; 55: 361-369.
25. Cidlowski JA, Bellingham DL, Powell-Oliver FE, Lubahn DB, Sar M. Novel antipeptide antibodies to the human glucocorticoid receptor: recognition of multiple receptor forms in vitro and distinct localization of cytoplasmic and nuclear receptors. Mol Endocrinol 1990; 4: 1427-1437.
26. Chapman MS, Askew DJ, Kuscuoglu U, Miesfeld RL. Transcriptional control of steroid-regulated apoptosis in murine thymoma cells. Mol Endocrinol 1996; 10: 967-978.
27. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998; 93: 531-541.
28. Helmberg A, Auphan N, Caelles C, Karin M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J 1995; 14: 452-460.
29. Kofler R. The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem Cell Biol 2000; 114: 1-7.
30. Nazareth LV, Thompson EB. Leukemic cell apoptosis caused by constitutively active mutant glucocorticoid receptor fragments. Recent Prog Horm Res 1995; 50: 417-421.
31. Kaspers GJ, Pieters R, Veerman AP. Glucocorticoid resistance in childhood leukemia. Int J Pediat Hematol/Oncol 1997; 4: 583-596.
32. Burnstein KL, Bellingham DL, Jewell CM, Powell-Oliver FE, Cidlowski JA. Autoregulation of glucocorticoid receptor gene expression. Steroids 1991; 56: 52-58.
33. Webster JC, Cidlowski JA. Downregulation of the glucocorticoid receptor. A mechanism for physiological adaptation to hormones. Ann NY Acad Sci 1994; 746: 216-220.
34. Shimojo M, Hiroi N, Yakushiji F, Ueshiba H, Yamaguchi N, Miyachi Y. Differences in down-regulation of glucocorticoid receptor mRNA by cortisol, prednisolone and dexamethasone in HeLa cells. Endocrine J 1995; 42: 629-636.
35. Andreae J, Tripmacher R, Weltrich R, Rohde W, Keitzer R, Wahn U, Paul K, Buttgereit F. Effect of glucocorticoid therapy on glucocorticoid receptors in children with autoimmune diseases. Pediatr Res 2001; 49: 1310-135.
36. Silva CM, Powell-Oliver FE, Jewell CM, Sar M, Allgood VE, Cidlowski JA. Regulation of the human glucocorticoid receptor by long-term and chronic treatment with glucocorticoid. Steroids 1994; 59: 436-442.
37. Pujols L, Mullol J, Perez M, Roca-Ferrer J, Juan M, Xaubet A, Cidlowski JA, Picado C. Expression of the human glucocorticoid receptor alpha and beta isoforms in human respiratory epithelial cells and their regulation by dexamethasone. Am J Respir Cell Mol Biol 2001; 24: 49-57.
38. Tonko M, Ausserlechner MJ, Bernhard D, Helmberg A, Kotler R. Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis. FASEB J 2001; 15: 693-699.
39. Ramdas J, Liu W, Harmon JM. Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res 1999; 59: 1378-1385.
40. Breslin MB, Geng CD, Vedeckis WV. Multiple promoters exist in the human gr gene, one of which is activated by glucocorticoids. Mol Endocrinol 2001; 15: 1381-1395.
41. Gametchu B, Chen F, Sackey F, Powell C, Watson CS. Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models. Steroids 1999; 64: 107-119.
42. Sackey FN, Watson CS, Gametchu B. Cell cycle regulation of membrane glucocorticoid receptor in CCRF-CEM human ALL cells: correlation to apoptosis. Am J Physiol 1997; 273: E571-583.
43. Karl M, Lamberts SWJ, Detera-Wadleigh SD, Encio IJ, Stratakis CA, Hurley DM, Accili D, Chrousos GP. Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab 1993; 76: 683-689.
44. Hurley DM, Accili D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, Constantine K, Taylor SI, Chrousos GP. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 1991; 87: 680-686.
45. Karl M, Lamberts SW, Koper JW, Katz DA, Huizenga NE, Kino T, Haddad BR, Hughes MR, Chrousos GP. Cushing's disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc Assoc Am Phys 1996; 108: 296-307.
46. Malchoff DM, Brufsky A, Reardon G, McDermott P, Javier EC, Bergh CH, Rowe D, Malchoff CD. A mutation of the glucocorticoid receptor in primary cortisol resistance. J Clin Invest 1993; 91: 1918-1925.
47. Ruiz M, Lind U, Gafvels M, Eggertsen G, Carlstedt-Duke J, Nilsson L, Holtmann M, Stierna P, Wikstrom AC, Werner S. Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin Endocrinol 2001; 55: 363-371.
48. Feng J, Zheng J, Bennett WP, Heston LL, Jones IR, Craddock N, Sommer SS. Five missense variants in the amino-terminal domain of the glucocorticoid receptor: no association with puerperal psychosis or schizophrenia. Am J Med Genet 2000; 96: 412-417.
49. Koper JW, Stolk RP, de Lange P, Huizenga NA, Molijn GJ, Pols HA, Grobbee DE, Karl M, de Jong FH, Brinkmann AO, Lamberts SW. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet 1997; 99: 663-668.
50. Huizenga NA, Koper JW, De Lange P, Pols HA, Stolk RP, Burger H, Grobbee DE, Brinkmann AO, De Jong FH, Lamberts SW. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998; 83: 144-151.
51. Lin RCY, Wang WYS, Morris BJ. High penetrance, overweight, and glucocorticoid receptor variant: case-control study. Br Med J 1999; 319: 1337-1338.
52. Hillmann AG, Ramdas J, Multanen K, Norman MR, Harmon JM. Glucocorticoid receptor gene mutations in leukemic cells acquired in vitro and in vivo. Cancer Res 2000; 60: 2056-2062.
53. Tissing WJE, Meijerink JPP, den Boer ML, Verschuuren A, Koper JW, Sonneveld P, Pieters R. Polymorphisms in the glucocorticoid receptor gene in childhood leukemia. Leukemia 2001; 15: 511 (Abstr.).
54. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635-641.
55. Oakley RH, Webster JC, Jewell CM, Sar M, Cidlowski JA. Immunocytochemical analysis of the glucocorticoid receptor alpha isoform (GRalpha) using GRalpha-specific antibody. Steroids 1999; 64: 742-751.
56. Longui CA, Vottero A, Adamson PC, Cole DE, Kino T, Monte O, Chrousos GP. Low glucocorticoid receptor alpha/beta ratio in T-cell lymphoblastic leukemia. Horm Metab Res 2000; 32: 401-406.
57. Tissing WJE, Lauten M, Meijerink JPP, den Boer ML, Verschuuren AC, Gerdes K, Beger C, Wiemer EAC, Sonneveld P, Welte K, Schrappe M, Pieters R. Glucocorticoid receptor splice variants alpha, beta and GR-P and in vivo glucocorticoid resistance in childhood acute lymphoblastic leukemia. Blood 2001; 98: 313a (Abstr.).
58. Oakley RH, Sar M, Cidlowski JA. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996; 271: 9550-9559.
59. Oakley RH, Webster JC, Sar M, Parker CR Jr, Cidlowski JA. Expression and subcellular distribution of the beta-isoform of the human glucocorticoid receptor. Endocrinology 1997; 138: 5028-5038.
60. Hecht K, Carlstedt-Duke J, Stierna P, Gustafsson J, Bronnegard M, Wikstrom AC. Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor. J Biol Chem 1997; 272: 26659-26664.
61. de Castro M, Elliot S, Kino T, Bamberger C, Karl M, Webster E, Chrousos GP. The non-ligand binding beta-isoform of the human glucocorticoid receptor (hGR beta): tissue levels, mechanism of action, and potential physiologic role. Mol Med 1996; 2: 597-607.
62. Carlstedt-Duke J. Glucocorticoid receptor beta: view II. Trends Endocrinol Metab 1999; 10: 339-342.
63. Vottero A, Chrousos GP. Glucocorticoid receptor beta: view I. Trends Endocrinol Metab 1999; 10: 333-338.
64. Leung DYM, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, Chrousos GP, Klemm DJ. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997; 186: 1567-1574.
65. Gagliardo R, Chanez P, Vignola AM, Bousquet J, Vachier J, Godard P, Bonsignore G, Demoly P, Mathieu M. Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma. Am J Respir Crit Care Med 2000; 162: 7-13.
66. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem 1999; 274: 27857-27866.
67. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435-2441.
68. de Lange P, Koper JW, Brinkmann AO, de Jong FH, Lamberts SW. Natural variants of the beta isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids. Mol Cell Endocrinol 1999; 153: 163-168.
69. Brogan IJ, Murray IA, Cerillo C, Needham M, White A, Davis JR. Interaction of glucocorticoid receptor isoforms with transcription factors AP-1 and NF-kappaB: lack of effect of glucocorticoid receptor beta. Mol Cell Endocrinol 1999; 157: 95-104.
70. Rivers C, Levy A, Hancock J, Lightman S, Norman M. Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab 1999; 84: 4283-4286.
71. Gerdes K, Beger C, Lauten M, Fernandez-Munoz I, Tissing WJE, Pieters R, Welte K, Schrappe M. Quantification of the glucocorticoid receptor and its splice variant gamma in childhood acute lymphoblastic leukemia using real-time PCR. Blood 2001; 98: 113a (Abstr.).
72. Ray DW, Davis JRE, White A, Clark AJL. Glucocorticoid receptor structure and function in glucocorticoid-resistant small cell lung carcinoma cells. Cancer Res 1996; 56: 3276-3280.
73. Moalli PA, Pillay S, Krett NL, Rosen ST. Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. Cancer Res 1993; 53: 3877-3879.
74. Krett NL, Pillay S, Moalli PA, Greipp PR, Rosen ST. A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. Cancer Res 1995; 55: 2727-2729.
75. Segeren CM, de Lange P, Wiemer E, Koper JW, Brinkman AO, De Jong FH, Lamberts SWJ, Sonneveld P. Preferential expression of a non-functional glucocorticoid receptor in hematological malignancies. Blood 1998; 92: 283b (Abstr.).
76. Segeren CM, Sonneveld P, de Lange P, Wiemer E, Koper JW, van Zon A, de Jong FH, Lamberts SWJ. Molecular mechanisms of therapy resistance in multiple myeloma: the role of the non-functional glucocorticoid receptor delta. Blood 1999; 94: 593a (Abstr.).
77. de Lange P, Segeren CM, Koper JW, Wiemer E, Sonneveld P, Brinkmann AO, White A, Brogan IJ, de Jong FH, Lamberts SW. Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells. Cancer Res 2001; 61: 3937-3941.
78. Bodwell JE, Webster JC, Jewell CM, Cidlowski JA, Hu JM, Munck A. Glucocorticoid receptor phosphorylation: overview, function and cell cycle-dependence. J Steroid Biochem Mol Biol 1998; 65: 91-99.
79. Bourgeois S, Gruol DJ, Newby RF, Rajah FM. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 1993; 7: 840-851.
80. Ueda K, Kino K, Taguchi Y, Yamada K, Saeki T, Tanigawara Y, Komano T. Role of P-glycoprotein in the transport of hormones and peptides. In: Gupta S, Tsuruo T (eds). Multidrug Resistance in Cancer Cells. John Wiley & Sons: Chichester, 1996, pp 303-319.
81. den Boer ML, Pieters R, Kazemier KM, Rottier MM, Zwaan CM, Kaspers GJ, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJ. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092-2098.
82. Wuchter C, Karawajew L, Ruppert V, Schrappe M, Harbott J, Ratei R, Dorken B, Ludwig WD. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 154-160.
83. Maung ZT, Hogarth L, Reid MM, Proctor SJ, Hamilton PJ, Hall AC. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukemia. Leukemia 1994; 8: 1487-1491.
84. Kearns PR, Pieters R, Rottier MM, Pearson AD, Hall AG. Raised blast glutathione levels are associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 2001; 97: 393-398.
85. Den Boer ML, Pieters R, Kazemier KM, Janka-Schaub GE, Henze G, Creutzig U, Kaspers GJ, Kearns PR, Hall AC, Pearson AD, Veerman AJ. Different expression of glutathione S-transferase alpha, mu and pi in childhood acute lymphoblastic and myeloid leukaemia. Br J Haematol 1999; 104: 321-327.
86. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K, Stanulla M. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000; 10: 715-726.
87. Pratt WB. The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem 1993; 268: 21455-21458.
88. Rajapandi T, Greene LE, Eisenberg E. The molecular chaperones Hsp90 and Hsp70 are both necessary and sufficient to activate hormone binding by glucocorticoid receptor. J Biol Chem 2000; 275: 22597-22604.
89. Kojika S, Sugita K, Inukai T, Saito M, Iijima K, Tezuka T, Goi K, Shiraishi K, Mori T, Okazaki T, Kagami K, Ohyama K, Nakazawa S. Mechanisms of glucocorticoid resistance in human leukemic cells: implication of abnormal 90 and 70 kDa heat shock proteins. Leukemia 1996; 10: 994-999.
90. Kanelakis KC, Morishima Y, Dittmar KD, Galigniana MD, Takayama S, Reed JC, Pratt WB. Differential effects of the hsp70-binding protein BAG-1 on glucocorticoid receptor folding by the hsp90-based chaperone machinery. J Biol Chem 1999; 274: 34134-34140.
91. Kullmann M, Schneikert J, Moll J, Heck S, Zeiner M, Gehring U, Cato AC. RAP46 is a negative regulator of glucocorticoid receptor action and hormone-induced apoptosis. J Biol Chem 1998; 273: 14620-14625.
92. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 1995; 15: 943-953.
93. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-290.
94. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-286.
95. Wang W, Wykrzykowska J, Johnson T, Sen R, Sen J. A NF-kappa B/c-myc-dependent survival pathway is targeted by corticosteroids in immature thymocytes. J Immunol 1999; 162: 314-322.
96. Ramdas J, Harmon JM. Glucocorticoid-induced apoptosis and regulation of NF-kappaB activity in human leukemic T cells. Endocrinology 1998; 139: 3813-3821.
97. Heck S, Bender K, Kullmann M, Gottlicher M, Herdich P, Cato AC. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J 1997; 16: 4698-4707.
98. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
99. Bailey S, Hall AG, Pearson AD, Redfern CP. The role of AP-1 in glucocorticoid resistance in leukaemia. Leukemia 2001; 15: 391-397.
100. Geley S, Fiegl M, Hartmann BL, Kofler R. Genes mediating glucocorticoid effects and mechanisms of their regulation. Rev Physiol Biochem Pharmacol 1996; 128: 1-97.
101. Thulasi R, Harbour DV, Thompson EB. Suppression of c-myc is a critical step in glucocorticoid-induced human leukemic cell lysis. J Biol Chem 1993; 268: 18306-18312.
102. Thompson EB, Medh RD, Zhou F, Ayala-Torres S, Ansari N, Zhang W, Johnson BH. Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of CEM cells and suppress c-myc. J Steroid Biochem Mol Biol 1999; 69: 453-461.
103. Medh RD, Wang A, Zhou F, Thompson EB. Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells. Oncogene 2001; 20: 4629-4639.
104. Martins TC, Aguas AP. Involvement of c-myc in the resistance of non-obese diabetic mice to glucocorticoid-induced apoptosis. Immunology 1998; 95: 377-382.
105. Löffler M, Ausserlechner MJ, Tonko M, Hartmann BL, Bernhard D, Geley S, Helmberg A, Kofler R. c-Myc does not prevent glucocorticoid-induced apoptosis of human leukemic lymphoblasts. Oncogene 1999; 18: 4626-4631.
106. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
107. Obexer P, Certa U, Kofler R, Helmberg A. Expression profiling of glucocorticoid-treated T-ALL cell lines: rapid repression of multiple genes involved in RNA-, protein- and nucleotide synthesis. Oncogene 2001; 20: 4324-4336.
108. Mann CL, Hughes FM Jr, Cidlowski JA. Delineation of the signalling pathways involved in glucocorticoid-induced and spontaneous apoptosis of rat thymocytes. Endocrinology 2000; 141: 528-538.
109. Hakem R, Hakem A, Duncan CS, Henderson JT, Woo M, Soengas MS, Elia A, de la Pompa JL, Kagi D, Khoo W, Potter J, Yoshida R, Kaufman SA, Lowe SW, Penninger JM, Mak TW. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998; 94: 339-352.
110. Kuida K, Haydar TF, Kuan CY, Gu Y, Taya C, Karasuyama H, Su MS, Rakic P, Flavell RA. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998; 94: 325-337.
111. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
112. Brady HJ, Salomons GS, Bobeldijk RC, Berns AJ. T cells from baxalpha transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. gene product in. EMBO J 1996; 15: 1221-1230.
113. Hartmann BL, Geley S, Loffler M, Hattmannstorfer R, Strasser-Wozak EM, Auer B, Kofler R. Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis. Oncogene 1999; 18: 713-719.
114. Alnemri ES, Fernandes TF, Haldar S, Croce CM, Litwack G. Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B- leukemias. Cancer Res 1992; 52: 491-495.
115. Caron-Leslie LA, Evans RB, Cidlowski JA. Bcl-2 inhibits glucocorticoid-induced apoptosis but only partially blocks calcium ionophore or cycloheximide-regulated apoptosis in S49 cells. FASEB J 1994; 8: 639-645.
116. Smets LA, Van den Berg J, Acton D, Top B, Van Rooij H, Verwijs-Janssen M. BCL-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 1994; 84: 1613-1619.
117. Salomons GS, Smets LA, Verwijs-Janssen M, Hart AA, Haarman EG, Kaspers GJ, Wering EV, Der Does-Van Den Berg AV, Kamps WA. Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia 1999; 13: 1574-1580.
118. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Arico M, Campana D. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996; 87: 1140-1146.
119. Haarman EG, Kaspers GJ, Pieters R, van Zantwijk CH, Broekema GJ, Hahlen K, Veerman AJ. BCL-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance. Adv Exp Med Biol 1999; 457: 325-333.